Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Amyloid beta (oligomeric form) (Aβ oligomers)
- Target
- Aβ oligomers
- Molecular classification
- Peptide aggregate, Protein aggregate
01
Overview
Amyloid beta (Aβ) oligomers are soluble aggregates of the amyloid beta peptide, derived from the amyloid precursor protein (APP). These oligomeric forms are distinct from monomers and insoluble fibrils/plaques and are considered key neurotoxic agents in Alzheimer’s disease pathogenesis. They disrupt synaptic function by binding to cell surface receptors and induce tau phosphorylation.
- Other names
- AβOsAmyloid beta oligomersOligomeric amyloid betaSoluble amyloid beta oligomers
02
Mechanism of action
AβO binding triggers redistribution of critical synaptic proteins and/or membrane insertion.
03
Biological functions
Synapse disruptionNeurotoxicityCalcium dysregulationReceptor bindingMembrane interaction
04
Disease associations
Alzheimer's diseaseNeurodegenerative disease
05
Safety considerations
Off-target effects due to structural heterogeneityBlood-brain barrier penetration challengesPotential for immune response against AβTargeting the correct oligomeric speciesComplexity in drug development because the target is an aggregate of the Amyloid beta peptide, not a single protein
06
Biomarkers
Aβ42/Aβ40 ratio in cerebrospinal fluidAmyloid PET imaging
Beyond the preview
Go deeper on Amyloid beta (oligomeric form) (Aβ oligomers).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amyloid beta (oligomeric form) (Aβ oligomers).